FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

725789008: Carbidopa monohydrate (substance)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2017. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3445284012 Carbidopa monohydrate (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3445285013 Carbidopa monohydrate en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
797701000172113 carbidopa monohydraté fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Carbidopa monohydrate (substance) Is a Carbidopa false Inferred relationship Some
Carbidopa monohydrate (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Dopamine receptor agonist (disposition) true Inferred relationship Some
Carbidopa monohydrate (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Dihydroxyphenylalanine decarboxylase inhibitor (disposition) true Inferred relationship Some
Carbidopa monohydrate (substance) Is a Dihydroxyphenylalanine true Inferred relationship Some
Carbidopa monohydrate (substance) This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. Carbidopa true Inferred relationship Some
Carbidopa monohydrate (substance) Is a Substance with dihydroxyphenylalanine decarboxylase inhibitor mechanism of action (substance) true Inferred relationship Some

Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely carbidopa (as carbidopa monohydrate) 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). False Carbidopa monohydrate (substance) Inferred relationship Some 1
Product containing precisely carbidopa (as carbidopa monohydrate) 25 milligram and levodopa 100 milligram/1 each prolonged-release oral tablet The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). False Carbidopa monohydrate (substance) Inferred relationship Some 1
Product containing precisely carbidopa (as carbidopa monohydrate) 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). False Carbidopa monohydrate (substance) Inferred relationship Some 2
Product containing precisely carbidopa (as carbidopa monohydrate) 25 milligram and levodopa 250 milligram/1 each conventional release oral tablet (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). False Carbidopa monohydrate (substance) Inferred relationship Some 2
Product containing precisely carbidopa (as carbidopa monohydrate) 10 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). False Carbidopa monohydrate (substance) Inferred relationship Some 2
Product containing precisely carbidopa (as carbidopa monohydrate) 12.5 milligram and levodopa 50 milligram/1 each conventional release oral tablet (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). False Carbidopa monohydrate (substance) Inferred relationship Some 2

This concept is not in any reference sets

Back to Start